Background: Immunomodulatory interventions play a key role in the treatment of infections and cancer as well as allergic diseases. Adjuvants such as micro-and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immune response. Here, we report the immunological assessment of novel and economically manufactured microparticle adjuvants, namely strontiumdoped hydroxyapatite porous spheres (SHAS), which we suggest for the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT). Methods and results: Scanning electron microscopy revealed that the synthesis procedure developed for the production of SHAS results in a highly homogeneous population of spheres. Strontium-doped hydroxyapatite porous spheres bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1. SHAS-OVA were taken up by human monocyte-derived dendritic cells (mdDCs) and murine DCs and did not have any necrotic or apoptotic effects even at high densities. In a murine model of ASIT for allergic asthmatic inflammation, we found that OVA released from subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4 + and CD8 + T cells. Allergen-specific
The mechanisms by which micro-and nanoparticles enhance immune responses to antigens are diverse and include the delivery of antigens and the direct stimulation of the immune cells, as recently reviewed (1) . The administration of an antigen in a particulate form has been postulated to enhance its stability and integrity and to create a so-called depot effect, where the antigen is gradually released, thus prolonging the challenge of the immune system (2) .
Allergen-specific immunotherapy (ASIT) is used as a desensitizing therapy for allergic diseases and is a specific and potentially curative treatment. The mechanisms of action of ASIT include the modulation of T-and B-cell responses and related antibody isotypes, as well as the regulation of eosinophils, basophils, and mast cells in terms of migration to the tissues and release of mediators (3) . Dendritic cells (DCs) as primer of the adaptive immune response are key cells for a successful ASIT. Recent research identified several subsets of DCs equipped with different functional properties, ranging from the induction of tolerance to the promotion of specific immune responses (4) . Subcutaneous immunotherapy protocols generally involve daily to weekly injections during a buildup phase, followed by monthly maintenance injections for a period of 3-5 years (5) . A prolonged presence of the antigen is needed for the induction of tolerance. Current ASIT protocols are time-consuming which leads to a low compliance of patients. Better therapeutic options are needed to meet this medical need.
The strontium-doped hydroxyapatite porous spheres (SHAS) used in this study are the result of an optimized synthesis procedure that allows for controlling their size, porosity, and morphology (6) . Similar spheres, hollow calcium phosphate spheres, have been shown to bind consistent amounts (~0.37 mg/mg) of the antibiotics vancomycin and cephalothin, which are then slowly released over many hours in vitro (7). In this study, we evaluated the potential of SHAS as a matrix for a prolonged local delivery of protein antigen, and we assessed their potential as a tolerance-inducing adjuvant for immunotherapeutic interventions, specifically ASIT.
Materials and methods
Preparation and characterization of SHAS, strontium-doped hydroxyapatite porous spheres NaCl, KCl, Na 2 HPO 4 , and KH 2 PO 4 were dissolved in sterile water at a molar ratio of 137.0 : 2.7 : 8.1 : 1.5 : 0.5. After addition of calcium chloride (1 mM), magnesium chloride (0.05 mM), and strontium nitrate (0.6 mM), the mixture was heated at 100°C. After 6 h, the precipitation was filtered and washed twice with room temperature ethanol. All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) at the highest purity grade available. The morphology of the spheres before and after ovalbumin (OVA) adsorption was analyzed by Field Emission Scanning Electron Microscopy (FE-SEM, LEO 1550; Zeiss, Jena, Germany). Powder X-ray diffraction (XRD, Siemens Diffractometer D5000; Siemens, Munich, Germany) using Cu Ka radiation (k = 1.5418
A) operated at 40 kV and 40 mA at a 2h range of 5-60°C was used to analyze the crystallinity of SHAS. Surface area and porosity were estimated from the N 2 sorption isotherm, which was performed by Accelerated Surface Area and Porosimetry (ASAP 2020; Micromeritics, Norcross, GA, USA) in accordance with the Brunauer-Emmet-Teller principle. The ion composition was analyzed using inductive coupled plasma optical emission spectroscopy (Optima 5300DV; Perkin-Elmer, Waltham, MA, USA). The zeta-potential of the particles was measured in phosphate-buffered saline (PBS) at 25 and 37°C by laser Doppler velocimetry on a ZetaSizer Nano instrument (Malvern Instruments, Malvern, UK). The refraction indexes used were of 1.63 for the particles. Lipopolysaccaride (LPS) contamination was ruled out indirectly measuring NF-jB activation in human mdDCs (data not shown).
Ovalbumin labeling
Grade VI OVA (Sigma-Aldrich) and Dylight 488 AmineReactive Dye (Thermo Scientific, Rockford, IL, USA) were used to produce labeled OVA 488 . To this end, OVA was suspended in PBS at a concentration of 2 mg/ml, sterilized by filtration, and added to the vial containing the dye. After 3-h incubation at room temperature and 12 h at 4°C, the unreacted dye was removed by dialysis against PBS with a SpectraPor Membrane with a molecular weight cutoff of 6-8 kDa (Spectrum Labs, Roncho Domingues, CA, USA) and four buffer exchanges over 36 h.
Protein loading of SHAS
SHAS (1-5 mg) were suspended in 500 ll PBS and put in a sonication bath five times for 10 s to obtain a homogeneous solution. Between each sonication burst, the tubes were shaken by hand. The SHAS were allowed to stand for 5 min, centrifuged (2000 g, 2 min), and washed once with 500 ll PBS. Afterward, they were suspended in 300 ll of 1 mg/ml protein solution per mg of particles and left overnight under constant shaking. Thereafter, the beads were collected by centrifugation (2000 g, 2 min) and the protein concentration in the supernatant was determined by Bradford (Bio-Rad, Hercules, CA, USA) to calculate the amount of protein loaded. The major cat allergen Fel d 1, used as a protein loading control for SHAS, was produced in Escherichia coli and purified as described (8) .
In vitro release
Two milligrams of OVA 488 -loaded SHAS was suspended in 200 ll PBS or PBS-Tween-20 (0.05%) and kept in suspension by rolling at room temperature. Spontaneous release was monitored by measuring the protein concentration in the supernatant after 20 h. The quality of the protein released was visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Residual protein bound to the SHAS was released by incubation for 5 min at 90°C in SDS-PAGE loading buffer (50 mM Trizma-HCl pH8, 5% glycerol, 2.5% b-mercaptoethanol, 50 lg/ml bromophenol blue, 10% dithiothreitol, all from Sigma-Aldrich).
Preparation of monocyte-derived dendritic cells
Human monocyte-derived dendritic cells (mdDCs) were prepared from peripheral blood mononuclear cells from healthy donors with written informed consent. The CD14 + population was isolated by AutoMACS using CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured at 10 6 /ml in six-well plates in cRPMI (RPMI 1640, 10% heat-inactivated FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 19 MEM vitamins, 19 MEM nonessential amino acids, 100 U/ml penicillin, 100 lg/ml streptomycin, 100 lg/ml kanamycin, all from Sigma-Aldrich) in the presence of 1000 U/ml GM-CSF (PeproTech, Hamburg, Germany) and 1000 U/ml IL-4 (Novartis, Basel, Switzerland) for 5 days. The successful differentiation to human mdDCs was confirmed by flow cytometric CD11c staining (clone 3.9; Biolegend, San Diego, CA, USA) together with the viability staining agent eFluor 780 (eBioscience, Vienna, Austria, data not shown). Cells were stained and analyzed using a FACS LSRII or a Canto system with DIVA software (BD Biosciences, Erembodegem-Aalst, Belgium).
In vitro toxicity, apoptosis detection assays
One hundred, 10, or 1 lg of SHAS was added to 2 9 10 5 human mdDCs in 200 ll cRPMI in a 96-well plate. After 24-h incubation, the cells were stained for Annexin and 7AAD with the PE Annexin V Apoptosis Detection Kit I (BD Biosciences) and analyzed by flow cytometry.
Mice
10 weeks old female B6 wild-type, C57BL/6, or BALB/c mice were housed under specific pathogen free conditions and handled in accordance with French and European directives with ethical approval from the Centre d'Immunologie de Marseille-Luminy. OT-I and OT-II mice have been previously described (9, 10) .
Sensitization and immunotherapy models
The models are described in Fig. S1 . B6 mice were injected subcutaneously into the lumbar area with either 50mg soluble OVA labeled with DyLight 488 (OVA 488 ), 50mg OVA 488 bound to microparticles (SHAS-OVA 488 ), or PBS. Mice were sacrificed 1, 4 or 7 day(s) after injection. Single cell suspension of draining inguinal lymph nodes were produced as previously described (11) . Migratory DCs were analyzed for their uptake of OVA488 by flow cytometry.
Preparation and adoptive transfer of labeled OT-I and OT-II cells

OVA-specific CD8
+ (OT-I) and OVA-specific CD4 + (OT-II)
T cells were isolated as previously described (11), labeled with CellTrace Violet (CTV; Invitrogen, Detection Technologies, Eugene, OR, USA), adoptively transferred and after 3 days isolated from the spleen and analyzed by flow cytometry (see Fig. S1A ).
Flow cytometry of mouse cells
Single-cell suspension of lymph nodes was produced as previously described (11) . Cells were stained and analyzed using a FACS LSRII or a Canto system with DIVA software (BD Biosciences). Cell viability was evaluated using Sytox (Invitrogen Inc., Cambridge, MA, USA). Anti-CD3 (17A2) was from Biolegend; TCR Va2 (6D6.6) was from Abcam, anti-CD45.1 (A20) was from eBioscience; anti-CD4 (RM4-5) and anti-CD8a (53-6.7) were from BD Pharmingen (San Diego, CA, USA).
For the analysis of the nodal DCs, the following antibodies were additionally used: anti-NK1.1 (PK136), anti-CD19 (6D5), anti-Ly-6G (1A8), and anti-CD64 (X54-5/7.1) from BioLegend; anti-CD11b (M1/70), anti-CD11c (N418), anti-MHC class II (MHC II; I-A/I-E) (M5/114. 15 
Microscopy
Fluorescent OVA (OVA 488 )-labeled SHAS (prepared as described above) were added to 300 000 mdDCs at a concentration of 25 lg/ml in cRPMI. After 12 h, the cells were washed once with PBS and resuspended in 200 ll PBS at 37°C. CellMask Orange Plasma membrane Stain (Thermo Scientific) was diluted 1 : 5000 in PBS, vortexed for 30 s, and sonicated for 1 min. After warming at 37°C for 3 min in a water bath, 100 ll of this solution was added to the mdDCs and incubated by rolling for 10 min at room temperature. Stained cells were washed twice with PBS and brought onto a microscope slide by cytospin (500 r.p.m., 2 min), fixed with 4% paraformaldehyde (Sigma-Aldrich), covered with Prolong Gold Antifade Reagent with DAPI (Thermo Scientific/Life Technologies, Waltham, MA, USA), and visualized by a Leica TCS SPE confocal microscope (Leica Microsystems, Heerbrugg, Switzerland).
Immunoglobulin ELISA
Nunc-Immuno Clear Flat-Bottom Maxisorp 96-well plates (Thermo Scientific) were coated by overnight incubation at 4°C with 100 ll of 10 lg/ml OVA in PBS. Unspecific bindings were avoided by 1-h incubation in 150 ll blocking buffer (1% BSA and 5% sucrose in PBS, all from Sigma-Aldrich). After washing, 100 ll of diluted sera (1 : 10 for IgE, 1 : 100 for IgG 2a , 1 : 100 000 for IgG 1 ) was added and incubated for 3 h. Ovalbumin-specific antibodies were detected with 100 ll of the corresponding biotinylated anti-isotype at 0.5 lg/ml and incubated for 2 h. After 45-min incubation with Streptavidin-HRP diluted 1 : 200 (R&D Systems, Minneapolis, MN, USA), bound antibodies were detected with OptiEIA TMB Substrate Reagent (BD Biosciences). Antibodies, sera, and enzymes were diluted in PBS containing 1% BSA. Between each step, plates were washed three times with PBS-Tween (0.05%). The following anti-isotype antibodies were used: biotin anti-mouse IgE (RME-1), biotin anti-mouse IgG 1 (RMG1-1), and biotin anti-mouse IgG 2a (RMG2a-62; all from Biolegend). Serum concentrations were calculated by four-parametric curve regression using the following antibodies as standards (50-0.4 ng/ml): mouse anti-OVA IgE (2C6; AbD Serotec, Raleigh, NC, USA), mouse antidenatured OVA IgG 1 , and mouse antidenatured OVA IgG 2a (6C8, 6G2; Thermo Scientific).
Bronchoalveolar lavage
Mice were killed by intraperitoneally injection of pentobarbital (150 mg/kg, Streuli Pharma AG, Uznach, Switzerland). Broncho alveolar lavage (BAL) was performed by sealing the upper part of the trachea with medical tweezers and injecting 1 ml PBS containing the cOmplete proteinase inhibitor cocktail (Roche, Mannhein, Germany), using a 1-ml syringe with a bent 26G needle. Cell type and content in BAL were determined by Romanowsky stain (Diff-Quick; Medion Diagnostics, D€ udingen, Switzerland) for cell subsets.
Behavioral assessments
To assess pain or discomfort, mice were observed in an open-field test. After immunotherapeutic injections, every mouse was allowed to rest for 45 min in the home cage. Afterward, it was transferred to a 30 9 50 cm cage divided into 10 
Statistical analysis
The Wilcoxon-Mann-Whitney test was used to assess statistical significance. Probability values are expressed as the following: ***P < 0.001; **P < 0.01; *P < 0.05; NS, nonsignificant.
Results
Physical characterization of SHAS
The synthesis procedure developed for the production of SHAS resulted in a homogeneous population of spheres as assessed by scanning electron microscopy (Fig. 1A) . The molar ratio of their composition was 1.00 (Magnesium): 2.15 (Strontium): 3.85 (Calcium): 5.42 (Phosphate). Strontium-doped hydroxyapatite porous spheres mainly consisted of hydroxyapatite as shown by XRD analysis, where peaks were coherent with the joint committee on powder diffraction standards (JCPDS) data (JCPDS-09-0432/1996, Fig. 1B) . The zeta-potential of SHAS in PBS resulted in a negative value of À10.5 AE 1.3 mv (mean AE SEM, n > 3) at 25°C and of À12.1 AE 4.0 mv at 37°C.
The spheres exhibited a spherical and porous shape. Scanning electron microscopy showed an average diameter of 1.8 lm, with a range of 1.3-2.5 lm. The pore size of 33.1 nm in spheres was obtained from BET analysis (Fig. 1C) . One milligram of SHAS bound approximately 90 lg of both the model antigen OVA and the control protein Fel d 1, the major cat allergen (Fig. 1D ). Ovalbumin binding did not influence the morphology of SHAS as demonstrated by electron microscopy (Fig. 1C) , and the particle-bound OVA did not appear degraded or modified after spontaneous or Tween-20-induced release (Fig. 1E) .
OVA-loaded SHAS is taken up by human mdDCs without toxic and apoptosis-inducing side-effects in vitro
To test the compatibility and properties of SHAS on human antigen-presenting cells, we added the particles to mdDCs. DyLight 488 -labeled OVA (OVA 488 ), previously loaded on SHAS (SHAS-OVA 488 ), was taken up and internalized by human mdDCs after 1-h incubation ( Fig. 2A) . No difference in toxicity or apoptosis induction compared to untreated human mdDCs was seen when different concentrations of soluble OVA 488 , SHAS-OVA 488, or SHAS alone were added to the cells (Fig. 2B) .
Uptake of antigens by DCs in vivo
To quantify the uptake of antigens in vivo, we injected either soluble OVA labeled with DyLight 488 (OVA 488 + DCs, we see a small but consistent uptake of OVA 488 bound to SHAS, which persisted for the total period of investigation of 7 days (Fig. 2D) . cells. They express a TCR specific for an OVA-derived peptide presented by H-2Kb and for an OVA-derived peptide presented by H2-Ab, respectively (9, 10) . Three days after adoptive transfer, the extent of OT-I and OT-II cell proliferation was determined by CTV dilution (Fig. S1A) . SHAS-OVA triggered a significantly higher proliferation of OT-I and OT-II cells than soluble OVA (Fig. 3A,B) . Furthermore, SHAS-OVA, but not soluble OVA, resulted in sustained Tcell proliferation for up to 6 and 8 days in CD4 + and CD8 + T cells, respectively.
OVA-specific IgE and IgG responses to SHAS-bound OVA are comparable to those obtained with soluble OVA
Next, we wanted to investigate the induction of antigenspecific IgE and IgG production in response to SHAS-OVA compared to soluble OVA. To do so, we used a standard protocol for sensitization to allergens consisting of a sensitization period with three weekly injections of SHAS-OVA or the adequate amount of OVA as well as injections with Alum-OVA, PBS, and SHAS alone as controls. Following the sensitization period, the challenge consisted of three injections of OVA at days 26, 27 and 28 (Fig. S1B) . Humoral responses, in particular serum levels of antigenspecific IgE, IgG 1, and IgG 2a , were comparable in mice immunized with SHAS-OVA and soluble OVA (Fig. 4A-C) . Moreover, following aerosol allergen challenge, the amount of eosinophils in the BAL fluid was comparable for sensitization with OVA, SHAS-OVA, and Alum-OVA, indicating analogous levels of allergic sensitization (Fig. 4D) .
SHAS immunotherapy has increased efficacy
To assess the potential of SHAS as an antigen carrier for immunotherapeutic interventions for allergic diseases, we used a rush immunotherapy protocol consisting of a sensitization period followed by treatment with OVA, SHAS-OVA, or protein-free SHAS. As control, we also added a group of mice (OVA-ctrl) treated more frequently and with a higher Figure 5 Strontium-doped hydroxyapatite porous spheres (SHAS) immunotherapy has reduced side-effects. After sensitization with Alum adsorbed OVA, mice were treated with two s.c. injections of OVA, SHAS, or SHAS-OVA (0.2 mg OVA) on days 21 and 28. As a control, higher amounts were injected three times every second day (OVA-Ctrl). Serum samples were collected throughout the experiment as well as the BAL fluid after kill. For experimental protocol, see Significant differences among the groups are marked (*P < 0.05; **P < 0.01; two-tailed Mann-Whitney test). Each group consisted of six animals, except for the SHAS control group, which consisted of four animals. BAL, broncho alveolar lavage.
dose of OVA (14) . After the treatment, mice were challenged with OVA (Fig. S1C) . Behavioral assessments evaluated pain and discomfort using a symptom score as described in the material and methods section. Immunotherapy using SHAS-OVA showed a stronger reduction in the symptoms assessed following both the first and the last immunotherapeutic injections than did soluble OVA or SHAS alone (Fig. 5A,B) . Regarding the other parameters assessed, such as eosinophils in BAL and antigen-specific IgG 1, no difference was seen between the groups treated with SHAS-OVA, soluble OVA, or SHAS alone (Fig. 5C,D) .
Discussion
Allergen-specific immunotherapy is a safe and effective treatment for type I respiratory allergies in humans. Better adjuvants could further improve ASIT, allowing to decrease the allergen dose and to simplify immunization schemes. The present study showed that the use of SHAS, strontium-doped hydroxyapatite spheres, in ASIT can help to target the allergen to DCs and thereby enhance ASIT efficacy. Specifically, SHAS can bind allergens, facilitate allergen-specific immune response, and improve the clinical outcome of ASIT.
The loading of SHAS with the model allergen OVA enhances OVA stability and integrity, creates sustained release and depot effects, and results in sustained immune responses after application in vivo. One single subcutaneous injection of the antigenloaded particles was sufficient to induce antigen-specific CD8 + and CD4 + effector T cells over at least 6 days. Allergens loaded on SHAS are taken up by DCs, and the microparticles do not have toxic or apoptosis-inducing effects. Importantly, in a mouse model of ASIT, SHAS-OVA led to a better symptom reduction compared to OVA alone. OVA 488 released from SHAS-OVA 488 was mostly taken up by CD11b + DCs. This DC subset constitutively produces retinoic acid and induces Foxp3+ regulatory T cells (15) . Targeting of this tolerogenic CD11b + DC subset could thus be one possible explanation for the successful ASIT using SHAS-bound proteins.
A main advantage of the use of allergen-delivery systems in immunotherapy is that the antigen release is continuous, which could make single shot treatments as effective as the currently employed and less convenient multiple dosage protocols (16, 17) . Biodegradable nanoparticles such as SHAS encapsulate allergens so that they are delivered in vivo in a delayed-continuous or pulsatile manner to modulate the resultant immune response and decrease the potential for adverse events (18) . Our study supports this hypothesis as the injection with the slowly and continuously released OVA bound to SHAS resulted in a better response compared to the injection of the soluble, directly available OVA.
We have previously shown that the production of SHAS is straightforward, relatively inexpensive and robust (6) . Strontium-doped hydroxyapatite porous spheres have been hitherto used as biomaterial for bone reconstruction, and now for the first time, they are used in the field of immunology (19, 20) . Here, we show that ASIT with SHAS-bound allergen is more effective than immunotherapy with soluble allergen. Taken together, these findings recommend further development of SHAS for the use in ASIT.
